Results 201 to 210 of about 150,615 (347)

Demystifying upper limb hybrid prostheses-a scoping review. [PDF]

Front Rehabil Sci
Walters S, Seminati E, Metcalfe B, Bailey NY, Pegg EC.   +4 more
europepmc   +1 more source

Decline in mean platelet volume in patients with patent foramen ovale undergoing percutaneous closure : cardiovascular topic

, 2014
Barış DÜZEL, Nihan Kahya Eren, Rida Berılğen, Uğur Kocabaş, Mustafa Gonencer, Cem Nazlı, Oktay Ergene   +6 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Patent quality and trade credit: Based on the perspective of knowledge breadth. [PDF]

PLoS One
Li Y, Wang M.
europepmc   +1 more source

Harnessing Large Language Models for Precision Topic Extraction and Technology Patent Nomination: A GPT-centric Methodology

Franck Tshibanda Nkolongo, Saïd Echchakoui, Mehdi Amoon   +2 more
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Tertiary Patents on Drugs Approved by the FDA.

JAMA Health Forum
Teng TW, Tu SS, Mooney H, Bendicksen L, Gabriele SME, Wouters OJ, Feldman WB.   +6 more
europepmc   +1 more source

Exploring the nanobody patent landscape: a focus on BCMA sequences and structural analysis. [PDF]

MAbs
Xu J, Wang Y, Yuan N, Hu G, Hu Y.
europepmc   +1 more source

A Data-Driven Approach to Investigate Technological Transition: Applying Topic Modeling and Hidden Markov Model to Patent Data

Jinseob Kim, Sungjoo Lee
openalex   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source